INTERVENTION 1:	Intervention	0
Intraductal Arm	Intervention	1
Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.	Intervention	2
doxorubicin hydrochloride	CHEBI:31522	98-123
surgery	OAE:0000067	155-162
breast cancer	DOID:1612	167-180
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically confirmed infiltrating carcinoma of the breast meeting any of the following criteria:	Eligibility	1
carcinoma	HP:0030731,DOID:305	38-47
breast	UBERON:0000310	55-61
T1-3, any N disease	Eligibility	2
disease	DOID:4,OGMS:0000031	12-19
Proven ductal carcinoma in situ	Eligibility	3
ductal carcinoma in situ	HP:0030075,DOID:0060074	7-31
Unresected disease	Eligibility	4
disease	DOID:4,OGMS:0000031	11-18
Planned mastectomy as definitive surgical procedure	Eligibility	5
Known or suspected metastatic disease allowed provided mastectomy is planned	Eligibility	6
disease	DOID:4,OGMS:0000031	30-37
Nonpalpable tumor allowed (e.g., initial T2-3 tumor that responded to preoperative therapy)	Eligibility	7
No inflammatory breast cancer or other T4 features	Eligibility	8
breast cancer	DOID:1612	16-29
Successful baseline ductogram	Eligibility	9
Baseline nipple aspiration procedure must identify a duct productive of nipple aspirate fluid	Eligibility	10
aspiration	HP:0002835	16-26
duct	UBERON:0000058	53-57
duct	UBERON:0000058	61-65
No severe nipple retraction	Eligibility	11
severe	HP:0012828	3-9
Hormone receptor status not specified	Eligibility	12
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
PATIENT CHARACTERISTICS:	Eligibility	13
patient	HADO:0000008,OAE:0001817	0-7
Female patients	Eligibility	14
female	PATO:0000383	0-6
Menopausal status not specified	Eligibility	15
ECOG performance status 0-2	Eligibility	16
Absolute neutrophil count 1,500/mm^3	Eligibility	17
Platelet count  100,000/mm^3	Eligibility	18
platelet count	CMO:0000029	0-14
Hemoglobin  9.0 g/dL	Eligibility	19
hemoglobin	CHEBI:35143	0-10
Creatinine  2 times upper limit of normal (ULN)	Eligibility	20
creatinine	CHEBI:16737	0-10
Bilirubin  2 times ULN	Eligibility	21
AST and ALT  2.5 times ULN	Eligibility	22
Not pregnant or nursing	Eligibility	23
Negative pregnancy test	Eligibility	24
Fertile patients must use effective contraception	Eligibility	25
No significant history of severe allergy to iodinated contrast material or debilitating anxiety that may not allow for a ductogram	Eligibility	26
history	BFO:0000182	15-22
severe	HP:0012828	26-32
allergy	HP:0012393	33-40
anxiety	HP:0000739,DOID:2030	88-95
PRIOR CONCURRENT THERAPY:	Eligibility	27
See Disease Characteristics	Eligibility	28
disease	DOID:4,OGMS:0000031	4-11
Prior preoperative chemotherapy, trastuzumab (HerceptinÂ®), or hormonal therapy allowed provided it was completed 7-14 days prior to study treatment	Eligibility	29
No prior radiation therapy, excisional biopsy, breast reduction, areolar surgery, or breast implant (present or past history of implant that was removed)	Eligibility	30
breast	UBERON:0000310	47-53
breast	UBERON:0000310	85-91
surgery	OAE:0000067	73-80
present	PATO:0000467	101-108
history	BFO:0000182	117-124
No other prior procedure that may have altered the breast ductal system in the ipsilateral breast	Eligibility	31
breast	UBERON:0000310	51-57
breast	UBERON:0000310	91-97
No other concurrent chemotherapy, radiotherapy, endocrine therapy, or biologic agents for breast cancer	Eligibility	32
radiotherapy	OAE:0000235	34-46
breast cancer	DOID:1612	90-103
No other concurrent investigational drugs	Eligibility	33
Concurrent bisphosphonates allowed	Eligibility	34
Outcome Measurement:	Results	0
Maximum Tolerated Dose (MTD)	Results	1
mtd	BAO:0001248	24-27
Maximum tolerated dose (MTD) of administering pegylated liposomal doxorubicin (PLD) into one duct of women with breast cancer awaiting mastectomy. MTD reflects highest dose of drug that did not cause Dose Limiting Toxicity (DLT) in more than 30% of patients.	Results	2
mtd	BAO:0001248	24-27
mtd	BAO:0001248	147-150
doxorubicin	CHEBI:28748,BAO:0000639	66-77
duct	UBERON:0000058	93-97
breast cancer	DOID:1612	112-125
drug	CHEBI:23888	176-180
Time frame: Until up to 30 days after PLD administration	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Intraductal Arm	Results	5
Arm/Group Description: Participants received intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer.	Results	6
doxorubicin hydrochloride	CHEBI:31522	121-146
surgery	OAE:0000067	178-185
breast cancer	DOID:1612	190-203
Overall Number of Participants Analyzed: 15	Results	7
Measure Type: Number	Results	8
Unit of Measure: milligrams  10	Results	9
Adverse Events 1:	Adverse Events	0
Total: 0/3 (0.00%)	Adverse Events	1
Dermatology other (right areolar eschar)  [1]0/3 (0.00%)	Adverse Events	2
right	HP:0012834	19-24
